BioSpace News Archive

Axial Therapeutics, today announced the publication in Nature Medicine of full results from its Phase 1b/2a clinical trial of AB-2004. AB-2004 is being studied as a potential new treatment for managing irritability associated with Autism Spectrum Disorder (ASD) in children and is the company’s lead gut-targeted, molecular therapeutic.

The report provides details about market size, market restraints, drivers, challenges, growth opportunities, and top companies in the market.

The report provides details about market size, market restraints, drivers, challenges, growth opportunities, and top companies in the market.

Cells push and pull on surrounding tissue to move in groups as they form organs in an embryo, track down invading bacteria, and as they become cancerous and spread.

The global pharma & healthcare market report points out the key trends and developments taking place in this business space in the ongoing COVID-19 times.

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, announced that Integrity Bio and LakePharma, two companies that it acquired last year, have fully transitioned to the Curia brand.

Q BioMed Inc. (OTCQB: QBIO), a biomedical acceleration and development company, focused on licensing, acquiring, and monetizing life science assets, outlines strategic directions and goals for 2022.

Lungpacer Medical, a leading medical device innovation company, today announced the introduction of the AeroPace™ System, a next generation product, into the RESCUE 3 pivotal clinical study studying faster ventilator independence.

Oncopeptides AB, a biotech company focused on the development of therapies for difficult-to-treat hematological diseases, will publish its report for the fourth quarter and year-end results 2021 on February 17.

Biofrontera AG, an international biopharmaceutical company, decided its American Depositary Shares should be delisted from the Nasdaq Capital Market and its reporting obligations with the Securities and Exchange Commission should be deregistered and terminated.